Aim: study the effect of Sacubitril/valsartan (SV) combination therapy on cardio-renal (CR) biomarkers in T2DM with preserved ejection fraction (pEF); diastolic dysfunction and or LVH on 2D echocardiogram (E) and elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP) >125.

Methodology: between July and Sept 2018, 109 T2DM patients aged 18-75 yrs, irrespective of baseline A1c, receiving SV were identified. Patients were analysed every 2-3months for CR biomarkers (body mass index (BMI), A1c, systolic (S) BP, diastolic (D) BP, Lipid profile (TC, LDL, TG, HDL), Hs-CRP, NT-ProBNP, creatinine, eGFR and microalbumin/creatinine ratio {UACR} and data presented at 1 yr. T2DM with H/O IHD, reduced EF(<50%) or wall motion abnormalities on E, malignancy, major surgery, hyperkalemia >5.5Meq/L and eGFR<45 were excluded. Baseline characteristics were analyzed using descriptive statistics. Continuous variables were analysed using paired and unpaired t-test expressed as mean ± standard error. For interaction between drug class, ANOVA was used and p value <0.05 was considered significant (S).

Results: Baseline characteristics: Male 43%, Female 66%. Avg (age 63.16 ±8.325yrs, BMI 30.45±5.52, A1c% 7.1±1.2, egfr 90.31±30.45, UACR mg/gm 180.07±553.4, hs-CRP mg/dl 2.53±3.41, NT-proBNP 370.07±543.30 Ng/L). 64.2% received canagliflozin, 11.9% liraglutide, 94.5% Metformin, 61.5% gliptins, 65.1% gliclazide, 44% calcium channel blockers and 100% statin (rosuvastatin) Baseline (B) to 1yr: There was S reduction in SBP, DBP, A1c, TC, LDL, HDL, UACR, hs-CRP and NT-ProBNP NT-proBNP: there was S reduction from B to 3 mths (84.26±31.86, p-0.009), 6mth - 12 mths (39.95±17.40,p-0.024) and B-12mths (155.69±744.10,p-0.001). There was no diff seen 3-6mths (38.09±38.03, p-0.320). There was an interaction seen with Liraglutide in terms of NT-proBNP and UACR.

Conclusion: SV may be effective in reducing NT-ProBNP in T2DM with pEF

Disclosure

V. Gupta: None. V. Teli: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.